Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia

被引:63
作者
Faderl, S
Do, KA
Johnson, MM
Keating, M
O'Brien, S
Jilani, I
Ferrajoli, A
Ravandi-Kashani, F
Aguilar, C
Dey, A
Thomas, DA
Giles, FJ
Kantarjian, HM
Albitar, M
机构
[1] Quest Diagnost, Nichols Inst, San Juan Capistrano, CA 92690 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
D O I
10.1182/blood-2005-03-1010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis plays an important role in solid tumors and hematologic malignancies. The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia (ALL) remains ambiguous. We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients. Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-1 receptor alpha (IL-1R alpha), IL-6, IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of 95 patients by enzyme-linked immunosorbent assay (ELISA). In a univariate Cox proportional hazards model, higher levels of IL-1R alpha, IL-8, VEGFR1, and VEGFR2 were predictive of poor survival. In contrast, higher levels of VEGF were predictive of longer survival, and higher levels of bFGF suggested a similar trend (P =.09). The multivariate model simultaneously included VEGF (relative risk [RR] for death, 8.01; P =.001 for levels less than or equal to 19.5 pg/mL), IL-1R alpha (RR, 5.12; P =.007 for levels greater than 373 pg/mL), and VEGFR2 (FIR, 4.01; P =.04 for levels greater than 8222 pg/mL) as independent factors for survival. Of interest is the association of high levels of VEGF with good prognosis and higher levels of VEGF receptors with poor outcome. These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL, and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents.
引用
收藏
页码:4303 / 4307
页数:5
相关论文
共 41 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]   Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].
Aguayo, A ;
Estey, E ;
Kantarjian, H ;
Mansouri, T ;
Gidel, C ;
Keating, M ;
Giles, F ;
Estrov, Z ;
Barlogie, B ;
Albitar, M .
BLOOD, 1999, 94 (11) :3717-3721
[3]   Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, HM ;
Estey, EH ;
Giles, FJ ;
Verstovsek, S ;
Manshouri, T ;
Gidel, C ;
O'Brien, S ;
Keating, MJ ;
Albitar, M .
CANCER, 2002, 95 (09) :1923-1930
[4]   Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies [J].
Albitar, M ;
Do, KA ;
Johnson, MM ;
Giles, FJ ;
Jilani, I ;
O'Brien, S ;
Cortes, J ;
Thomas, D ;
Rassenti, LZ ;
Kipps, TJ ;
Kantarjian, HM ;
Keating, M .
CANCER, 2004, 101 (05) :999-1008
[5]  
Aref S, 2002, Hematology, V7, P273, DOI 10.1080/1024533021000037207
[6]   THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES [J].
BASILICO, C ;
MOSCATELLI, D .
ADVANCES IN CANCER RESEARCH, 1992, 59 :115-165
[7]   The thin red line: Angiogenesis in normal and malignant hematopoiesis [J].
Bertolini, F ;
Mancuso, P ;
Gobbi, A ;
Pruneri, G .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (09) :993-1000
[8]  
BIKFALVI A, 1994, LEUKEMIA, V8, P523
[9]  
Brizzi MF, 1999, CIRC RES, V84, P785
[10]  
Clark L.A., 1992, STAT MODELS S, P377